Revisiting arrhythmic risk after alcoholseptal ablation: Is the pendulum finally swinging... Back to myectomy?

JACC: Heart Failure

Volumn 2, Issue 6, 2014, Pages 637-640

  Maron, Barry J ^a   Nishimura, Rick A ^b  

^a MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Alcohol septal ablation; Hypertrophic cardiomyopathy; Sudden cardiac death; Surgical myectomy

Indexed keywords

ABLATION THERAPY; ALCOHOL SEPTAL ABLATION; ARRHYTHMIC RISK; CARDIOVASCULAR RISK; COMPARATIVE EFFECTIVENESS; EDITORIAL; HEART ARRHYTHMIA; HEART BLOCK; HEART INFARCTION; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART SURGERY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MUSCLE RESECTION; PATIENT SAFETY; PRIORITY JOURNAL; SUDDEN DEATH; TREATMENT RESPONSE;

EID: 84961751086     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.07.008     Document Type: Editorial

References (32)

1. Maron B.J., Maron M.S. Hypertrophic cardiomyopathy. Lancet 2013, 381:242-255.
2. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Committee to Develop an Expert Consensus Document on Hypertrophic Cardiomyopathy. JAm Coll Cardiol 2003, 42:1687-1713.
3. Gersh B.J., Maron B.J., Bonow R.O., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 124:2761-2796.
4. Maron B.J. Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 2007, 116:196-206.
5. Maron B.J., Rastegar H., Udelson J.E., Dearani J.A., Maron M.S. Contemporary surgical management of hypertrophic cardiomyopathy, the need for more myectomy surgeons and disease-specific centers, and the Tufts initiative. Am J Cardiol 2013, 112:1512-1515.
6. Maron B.J., Ommen S.R., Semsarian C., Spirito P., Olivotto I., Maron M.S. Hypertrophic cardiomyopathy present and future with translation into contemporary cardiovascular medicine. JAm Coll Cardiol 2014, 64:83-99.
7. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995, 346:211-214.
8. Sorajja P., Ommen S.R., Holmes D.R., et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2012, 126:2374-2380.
9. Sorajja P., Valeti U., Nishimura R.A., et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008, 118:131-139.
10. Qin J.X., Shiota T., Lever H.M., et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. JAm Coll Cardiol 2001, 38:1994-2000.
11. Nagueh S.F., Groves B.M., Schwartz L., et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. JAm Coll Cardiol 2011, 58:2322-2328.
12. Agarwal S., Tuzcu E.M., Desai M.Y., et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. JAm Coll Cardiol 2010, 55:823-834.
13. Kwon D.H., Kapadia S.R., Tuzcu E.M., et al. Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. JAm Coll Cardiol Intv 2008, 1:432-438.
14. ten Cate F.J., Soliman O.I., Michels M., et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail 2010, 3:362-369.
15. Noseworthy P.A., Rosenberg M.A., Fifer M.A., et al. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Am Cardiol 2009, 104:128-132.
16. Cuoco F.A., Spencer W.H., Fernandes V.L., et al. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. JAm Coll Cardiol 2008, 52:1718-1723.
17. Ralph-Edwards A., Woo A., McCrindle B.W., et al. Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. JThorac Cardiovasc Surg 2005, 129:351-358.
18. van der Lee C., ten Cate F.J., Geleijnse M.L., et al. Percutaneous versus surgical treatmetn for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. Circulation 2005, 112:482-488.
19. Nishimura R.A., Ommen S.R. Septal reduction therapy for obstructive hypertrophic cardiomyopathy and sudden death: what statistics cannot tell you. Circ Cardiovasc Interv 2010, 3:91-93.
20. Maron B.J., Dearani J.A., Ommen S.R., et al. The case for surgery in obstructive hypertrophic cardiomyopathy. JAm Coll Cardiol 2004, 44:2044-2053.
21. Ommen S.R., Maron B.J., Olivotto I., et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. JAm Coll Cardiol 2005, 46:470-476.
22. Maron B.J., Braunwald E. Evolution of hypertrophic cardiomyopathy to a contemporary treatable disease. Circulation 2012, 126:1640-1644.
23. Valeti U.S., Nishimura R.A., Holmes D.R., et al. Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. JAm Coll Cardiol 2007, 49:350-357.
24. Sherrid M.V., Shetty A., Winson G., et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil. Circ Heart Fail 2013, 6:694-702.
25. Maron B.J., Yacoub M., Dearani J.A. Benefits of surgery for obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients. Eur Heart J 2011, 32:1055-1058.
26. Vriesendorp P.A., Liebregts M., Steggerda R.C., et al. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JAm Coll Cardiol HF 2014, 2:630-636.
27. McLeod C.J., Ommen S.R., Ackerman M.J., et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 2007, 28:2583-2588.
28. Maron B.J. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet 2000, 355:425-426.
29. Spirito P., Maron B.J. Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. JAm Coll Cardiol 1999, 33:1071-1075.
30. Maron B.J., Ommen S.R., Nishimura R.A., Dearani J.A. Myths about surgical myectomy: rumor of its death have been greatly exaggerated. Am J Cardiol 2008, 101:887-889.
31. Dearani J.A., Ommen S.R., Gersh B.J., Schaff H.V., Danielson G.K. Surgery insight: septal myectomy for obstructive hypertrophic cardiomyopathy-the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med 2007, 4:503-512.
32. Maron B.J. Hypertrophic cardiomyopathy centers. Am J Cardiol 2009, 104:1158-1159.